World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
107
Citations
55287
World Ranking
6138
National Ranking
235

Overview

Edo Vellenga is affiliated with the University Medical Center Groningen in the Netherlands. Their research focuses predominantly within the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with a specialized emphasis on Hematology, Genetics, Molecular Biology, Oncology, and Physiology.

The scientist's main topics of work include:

  • Acute Myeloid Leukemia Research
  • Multiple Myeloma Research and Treatments
  • Blood disorders and treatments
  • Telomeres, Telomerase, and Senescence
  • Hematopoietic Stem Cell Transplantation
  • Acute Lymphoblastic Leukemia research
  • Myeloproliferative Neoplasms: Diagnosis and Treatment

Among the recent publications by Edo Vellenga are:

  • Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes, 2020, New England Journal of Medicine
  • Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion-Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study, 2020, Journal of Clinical Oncology
  • Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial, 2021, Blood Advances
  • The IL1-IL1RAP axis plays an important role in the inflammatory leukemic niche that favors acute myeloid leukemia proliferation over normal hematopoiesis, 2020, Haematologica
  • Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS, 2020, Leukemia

Frequent publication venues where Edo Vellenga's work appears include:

  • Blood Advances
  • Leukemia
  • Blood
  • Experimental Hematology
  • New England Journal of Medicine

Frequent collaborators in their research include:

  • Gerwin Huls
  • Walter J. F. M. van der Velden
  • Okke de Weerdt
  • Saskia K. Klein
  • Bob Löwenberg

Best Publications

  • Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)

    Daniel J. Klionsky;Amal Kamal Abdel-Aziz;Sara Abdelfatah;Mahmoud Abdellatif

  • Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

    Daniel J. Klionsky;Kotb Abdelmohsen;Akihisa Abe;Joynal Abedin

  • Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial

    Pieter Sonneveld;Ingo G.H. Schmidt-Wolf;Bronno Van Der Holt;Laila El Jarari

  • High-dose daunorubicin in older patients with acute myeloid leukemia.

    Bob Löwenberg;Gert J. Ossenkoppele;Wim van Putten;Harry C. Schouten

  • Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)

    Hagop M. Kantarjian;Neil P. Shah;Jorge E. Cortes;Michele Baccarani

  • Prognostic Index for Adult Patients With Acute Myeloid Leukemia in First Relapse

    Dimitri A. Breems;Wim L.J. Van Putten;Peter C. Huijgens;Gert J. Ossenkoppele

  • Cytarabine dose for acute myeloid leukemia.

    Bob Lowenberg;Thomas Pabst;Edo Vellenga;Wim van Putten

  • Uncovering regulatory pathways that affect hematopoietic stem cell function using 'genetical genomics'.

    Leonid Bystrykh;Ellen Weersing;Bert Dontje;Sue Sutton

  • The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemia

    G. Klein;Edo Vellenga;Marco Fraaije;Willem Kamps

  • Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes

    Pierre Fenaux;Pierre Fenaux;Uwe Platzbecker;Ghulam J. Mufti;Guillermo Garcia-Manero

  • Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin.

    Javier de Serna;Pau Montesinos;Edo Vellenga;Chelo Rayón

  • Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors

    Pau Montesinos;Juan M. Bergua;Edo Vellenga;Chelo Rayón

  • Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients

    Annemiek Broyl;Dirk Hose;Henk Lokhorst;Yvonne de Knegt

  • A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma

    Henk M. Lokhorst;Bronno van der Holt;Sonja Zweegman;Edo Vellenga

  • Ultrastructural study shows morphologic features of apoptosis and para-apoptosis in megakaryocytes from patients with idiopathic thrombocytopenic purpura

    Ewout J. Houwerzijl;Nel R. Blom;Johannes J. L. van der Want;Mariet T. Esselink

  • BLUEPRINT to decode the epigenetic signature written in blood

    David Adams;Lucia Altucci;Stylionos E. Antonarakis;Juan Ballesteros

  • Clinical, Molecular, and Prognostic Significance of WHO Type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and Various Other 3q Abnormalities in Acute Myeloid Leukemia

    Sanne Lugthart;Stefan Gröschel;H. Berna Beverloo;Sabine Kayser

  • Effects of recombinant human interleukin-6 in cancer patients: a phase I-II study

    M. M. Van Gameren;P. H. B. Willemse;N. H. Mulder;P. C. Limburg

  • Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356

    Daniel J. Klionsky;Kotb Abdelmohsen;Akihisa Abe;Joynal Abedin

  • Tissue distribution of the death ligand TRAIL and its receptors

    Diana C. Spierings;Elisabeth G. de Vries;Edo Vellenga;Fiona A. van den Heuvel

Frequent Co-Authors

Jan Jacob Schuringa
Jan Jacob Schuringa University Medical Center Groningen
Bob Löwenberg
Bob Löwenberg Erasmus MC
Pieter Sonneveld
Pieter Sonneveld Erasmus University Rotterdam
Sonja Zweegman
Sonja Zweegman Amsterdam UMC
Joost H.A. Martens
Joost H.A. Martens Radboud University
Miguel A. Sanz
Miguel A. Sanz University of Valencia
Elisabeth G.E. de Vries
Elisabeth G.E. de Vries University Medical Center Groningen
Gerald de Haan
Gerald de Haan University Medical Center Groningen

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re exploring options beyond a traditional MD program, several online degrees and healthcare careers offer flexible entry points and valuable opportunities. Medical billing and coding is a fast-growing field where students can start with medical billing and coding online courses cost far less than many in-person alternatives. These programs often allow you to begin working in healthcare administration within a year.

Nursing remains a versatile career path—online study options include everything from entry-level RN to advanced practitioner. Curious about how much it costs? Learn more about how much is online nursing school and find affordable programs tailored to your goals.

For registered nurses aiming to advance, the cheapest online np programs make becoming a Nurse Practitioner accessible and budget-friendly. Likewise, ambitious nurses can earn a doctorate through the cheapest dnp programs online, opening doors to teaching, leadership, and research.

Each of these pathways provides distinct advantages in terms of flexibility, career security, and cost. Online education in healthcare continues to expand, making it easier to enter or advance in the medical field from anywhere.

Best Scientists Citing Edo Vellenga

Trending Scientists